San Francisco, CA - endpoint, an interactive response technology (IRT) solutions provider, introduces its new clinical supply management tool DRIVE, which enables IRT functionality for non-IRT and Investigator-Sponsored Trials (IIT). DRIVE will be unveiled at the Drug Information Association (DIA) Annual Meeting, June 26-30, in Philadelphia. DRIVE delivers the benefits of IRT supplies management to the entire development program, including early-phase non-IRT and IIT, in one system - saving sponsors and sites time, reducing waste and optimizing the supply chain. Features include:
“While individual, stand-alone IRT systems for patient and supplies management are not warranted for every study, the challenge of managing supplies across IRT and non-IRT studies, including IIT, remains a sponsor pain point. To alleviate this issue, endpoint has developed DRIVE, a dynamic, easy-to-use clinical supply management hub,” said Chuck Harris, general manager. “DRIVE reflects endpoint’s commitment to addressing our industry’s challenges with novel, SaaS-based solutions.” endpoint will also be unveiling its new brand, which showcases endpoint’s services and technology by both highlighting the company’s proven expertise and emphasizing PULSE as a reliable IRT solution. Stop by Booth 501 at DIA or
schedule a meeting
to ask about endpoint’s feature-rich supply chain and clinical management tools and see how it gets
Straight to the Point
.
About endpoint
endpoint is focused primarily on providing interactive response technology (IRT) systems and solutions that support the life sciences industry. endpoint’s proprietary IRT system configuration engine, PULSE, provides non-technical users with the necessary tools to design and deploy customized IRT solutions in just four weeks. Having a team with up to 20 years of industry experience and headquartered in San Francisco, endpoint has been developing IRT systems since 2009. See how our flexible IRT solution meets the unique needs of any clinical trial at
www.endpointclinical.com
.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.